The global stem cell therapy market size was exhibited at USD 14.15 billion in 2023 and is projected to hit around USD 49.11 billion by 2033, growing at a CAGR of 13.25% during the forecast period 2024 to 2033.
Key Takeaways:
Market Overview
Stem cells have remarkable ability to renew themselves within the body. Stem cells are found in human body in an early stage of life as well as in adults and can differentiate into specialized cells types of a tissue or an organ.
Enormous amounts are being invested into stem cell therapy research since more than 50 years because of its unique property to divide and replicate over and over again. In addition, their unspecialized nature enables them to become varied variety of tissue types which makes them able to use in regenerative medicine. Furthermore, embryonic stem cells can form a whole new organ. Almost all the stem cell therapies are still into research phase. Very few treatments have been approved by regulatory bodies and also require specific criteria to meet before a patient undergoes the treatment.
Market players are investing more in oncology to provide better clinical solutions to cancer patients. Even though, chemotherapy is one of the effective tools used to treat cancers, it has some serious side effects which kills bone marrow, and further leads to the death of a patient. To overcome this problem and to improve life expectancies of cancer patients, researchers are constantly working on stem cell therapy. Moreover, researchers are also discovering novel therapies for cardiac problems, arthritis, diabetes, spinal cord injury, autoimmune disorders and many more.
There has been a constant growth in the research associated with the stem cell activities and the number of approval start come from the authorities have increased due to which the market for the stem cell therapy has grown well in the past and it is expected to grow during the forecast period. Due to constant research and development activities in the stem cell treatment market there has been a growth in the demand for the gene treatments and the cell treatments with the help of the stem cells. There has been an increased number of clinical trials that have been registered and they may affect the demand of this market to a great extent and lead to an increased sale.
In the developed nations and other nations that have a good spending power the demand for various medicines of the innovative nature is expected to grow well in the coming years as they may be helpful in treating different types of disorders like the cardiovascular disorders, neurological disorders and the autoimmune disorders. The stem cell treatment or therapy market is expected to grow due to an increase in the number of all of these diseases across the globe. There has also been an increased funding that has led to the growth of the market in the past. There is potential life in the human embryo and destroying the embryo is not ethical even though it is used in the treatment and it may be helpful in saving the lives.
During the outbreak of the pandemic which affected the global economy at large discovered 19 pandemic header good impact on the stem cell treatment market. For treating the virus, the stem cells have been used for various clinical trials. Due to the use of the regenerative medicines a better treatment can be offered for the patients that will help in reducing the cases to a great extent. It may also be helpful in reducing the rate of infection among the people. In the coming years the demand for this product is expected to grow as many clinical trials or getting clearance from the authorities. As there has been an increase in the number of various chronic diseases across the globe the demand for stem cell therapy is expected to grow and these increasing number of diseases will provide opportunities for the growth of the market in the coming years.
Constant research and development activities have provided novel therapies. iPSC’s Are used on a large scale by different research scientists across the globe for conducting studies against cancer. This product has been used in the clinical trials against the Parkinson's disease, Alzheimer's disease etc. increase in the number of these trials were led to the growth of the market in the coming years. During the pandemic the researchers were concentrating on providing treatment for combating the COVID-19 virus. The use of the stem cells for treating COVID-19 has been effective. In order to improve the research activities associated with the stem cell market Australian government has invested and provided a road map for the upcoming 10 years.
Stem Cell Therapy Market Report Scope
Report Coverage | Details |
Market Size in 2024 | USD 16.02 Billion |
Market Size by 2033 | USD 49.11 Billion |
Growth Rate From 2024 to 2033 | CAGR of 13.25% |
Base Year | 2023 |
Forecast Period | 2024-2033 |
Segments Covered | Product, Therapy Type, Application, Technology, End User, Geography |
Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
Regional Scope | North America; Europe; Asia Pacific; Central and South America; the Middle East and Africa |
Key Companies Profiled | Caladrius, CELGENE CORPORATION, ReNeuron Group plc, Virgin Health Bank, Opexa Therapeutics, Inc., Pluristem Therapeutics Inc, STEMCELL Technologies Inc., Biovault family, Precious Cells International, Ltd, Mesoblast Ltd, Seneca Biopharmaceuticals, Inc. |
Growth Factors
In the year 2021, it was seen that the chronic diseases had increased by about 58% and this data was provided by the World Health Organization. As the developing nations are highly populated, they have the maximum number of chronic diseases and the demand for the treatment of these diseases is expected to grow in this region. The cases of the Alzheimer's disease have increased to a great extent in the North American region especially in the United States. the number of patients that may suffer with Alzheimer's by the year 2032its projected to be 8.5 million. This is yet another reason why the market is expected to grow due to an increased rate of the people suffering with various chronic diseases.
Constant awareness regarding the availability of the therapies that make use of stem cells have led to an increased demand for the innovation and development of the system. Most of the market players are concentrating on forming collaborations in order to improve their research and development activities which may be helpful in increasing the market for the stem cell treatment across the developing as well as the developed nations in the coming years. There has been an increased amount of funding which has been invested further research that is cell based. There is a growing demand for the induced pluripotent stem cells which involves the genetic reprogramming of the stem cells of the adult human body in order to gather the stem cells of the embryonic stage. It happens to be a great alternative for the embryonic stem cells in the market.
Return increase number of funding which comes from the private as well as the public organizations there shall be an increase in the number of products used for the treatment of various diseases. The market is expected to grow maximum in the North American region and there shall be an increased sales or they shall be an increased demand for this therapy in the North American region during the forecast period. Followed by the North American region the Asia Pacific and the European region is also expected to have a good demand for the stem cell treatment during the forecast period.
Segments Insights:
Type Insights
Depending upon the type, the allogeneic stem cell therapy segment accounted for about 59% in the 2023. As the allogenic stem cell segment has seen a growing demand in the past which is due to the usage in treatment against cancer and the growing number of cases of this dreadful disease will create a greater demand in the coming years. With the help of the immune system cells the cancerous cells can be killed and these cells can be acquired from a donor. The segment is expected to grow well in the coming years due to its increased application for treating different types of cancers like leukemia lymphoma and myeloma.
Apart from the growing demand for to allogeneic segment the autologous segment is also expected to grow well in the coming years the autologous therapy segment is expected to grow at a higher compound annual growth rate in the coming years. As the use of this therapy reduces the chances of complications the market is expected to grow well. Also, the use of this therapy is expected to grow well in the coming years due to the lower chances of the rejection of the graft. The use of this treatment has largely affected the market as the survival rates have increased. This segment is expected to grow well in the coming years as it is affordable as compared to the other type. This happens to be a low-risk alternative.
Application Insights
Depending upon the basis of application, the region relative medicine segment is expected to have the largest share in the market in the coming years. The segment has dominated the market in the past with a share of about 92% and it is expected to grow well in the coming years. The demand for regenerative medicine especially for the neurological disorders is expected to grow in the coming years as that has been an increased number of approvals that are associated with the clinical trials for treating different types of diseases. Governments of various nations are increasing their investments for developing the regenerative medicines. These medicines will be helpful in treating different chronic disorders, diabetes, heart disease and blood disorder.
Apart from the growing demand of the stem cell therapy or the stem cells market for various regenerative medicines they shall be good demand for the development and the discovery of the drugs.
End User Insights
On the basis of the end user, the hospital segment is expected to have a dominant position in the coming years. The way level infrastructure and the different types of treatment options will help in the growth of the market in the coming years. As the hospitals have been instrumental in providing good treatment to the patience due to their association with the various research institutes which help them in coming up with novel therapies against various diseases these collaborations have being extremely favorable for the growth of the market in the past and they shall be instrumental in developing the market in the future.
Stem Cell Therapy Market in the U.S. 2024 To 2033
The U.S. stem cell therapy market size was valued at USD 5.32 billion in 2023 and is expected to reach USD 15.97 billion by 2033, growing at a CAGR of 13% from 2024 to 2033.
The North American region has dominated the market in the past and it is expected to have a dominant position even in the coming years. This region had a share of about 55% in the past as major manufacturing units are present in the North American region. The availability of the research and development units and advanced infrastructure in the healthcare segment shall be instrumental in the growth of the market. Constant reforms in this nation that are supportive for the healthcare sector and the presence of favorable reimbursement policies will play a great role in the growth of the market. Initiatives taken by the government in the United States are highly favorable for the research activities.
Constant promotion and awareness regarding the use of this therapies for various diseases through these organizations will be instrumental in increasing the demand for the treatment. The Asia Pacific region is also expected to grow well in the coming years and it is expected to grow at the highest compound annual growth rate of about 9.2% in the coming years. Favorable initiatives from the government and increased research activities will be helpful in the development of the stem cell treatments market in the Asia Pacific region.
Key Market Developments
Some of the prominent players in the Stem cell therapy market include:
Segments Covered in the Report
This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Nova one advisor, Inc. has segmented the global stem cell therapy market.
By Product
By Therapy Type
By Application
By Technology
By End User
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Channel Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Stem Cell Therapy Market
5.1. COVID-19 Landscape: Stem Cell Therapy Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Stem Cell Therapy Market, By Product
8.1. Stem Cell Therapy Market, by Product, 2024-2033
8.1.1. Adult Stem Cells (ASCs)
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Human Embryonic Stem Cells (HESCs)
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Induced Pluripotent Stem Cells (iPSCs)
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Very Small Embryonic Like Stem Cells
8.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Stem Cell Therapy Market, By Therapy Type
9.1. Stem Cell Therapy Market, by Therapy Type, 2024-2033
9.1.1. Autologous
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Allogenic
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Stem Cell Therapy Market, By Application
10.1. Stem Cell Therapy Market, by Application, 2024-2033
10.1.1. Regenerative Medicine
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Drug Discovery and Development
10.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Stem Cell Therapy Market, By Technology
11.1. Stem Cell Therapy Market, by Technology, 2024-2033
11.1.1. Cell Acquiition
11.1.1.1. Market Revenue and Forecast (2021-2033)
11.1.2. Cell Production
11.1.2.1. Market Revenue and Forecast (2021-2033)
11.1.3. Cryopreservation
11.1.3.1. Market Revenue and Forecast (2021-2033)
11.1.4. Expansion and Sub-Culture
11.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 12. Global Stem Cell Therapy Market, By End User
12.1. Stem Cell Therapy Market, by End User, 2024-2033
12.1.1. Hospitals
12.1.1.1. Market Revenue and Forecast (2021-2033)
12.1.2. Research institutes
12.1.2.1. Market Revenue and Forecast (2021-2033)
12.1.3. surgical institutes
12.1.3.1. Market Revenue and Forecast (2021-2033)
12.1.4. Orders
12.1.4.1. Market Revenue and Forecast (2021-2033)
Chapter 13. Global Stem Cell Therapy Market, Regional Estimates and Trend Forecast
13.1. North America
13.1.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.1.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.4. Market Revenue and Forecast, by Technology (2021-2033)
13.1.5. Market Revenue and Forecast, by End User (2021-2033)
13.1.6. U.S.
13.1.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.1.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.6.4. Market Revenue and Forecast, by Technology (2021-2033)
13.1.6.5. Market Revenue and Forecast, by End User (2021-2033)
13.1.7. Rest of North America
13.1.7.1. Market Revenue and Forecast, by Product (2021-2033)
13.1.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.1.7.3. Market Revenue and Forecast, by Application (2021-2033)
13.1.7.4. Market Revenue and Forecast, by Technology (2021-2033)
13.1.7.5. Market Revenue and Forecast, by End User (2021-2033)
13.2. Europe
13.2.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.2.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.4. Market Revenue and Forecast, by Technology (2021-2033)
13.2.5. Market Revenue and Forecast, by End User (2021-2033)
13.2.6. UK
13.2.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.2.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.6.4. Market Revenue and Forecast, by Technology (2021-2033)
13.2.6.5. Market Revenue and Forecast, by End User (2021-2033)
13.2.7. Germany
13.2.7.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.2.7.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.7.4. Market Revenue and Forecast, by Technology (2021-2033)
13.2.7.5. Market Revenue and Forecast, by End User (2021-2033)
13.2.8. France
13.2.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.8.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.2.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.8.4. Market Revenue and Forecast, by Technology (2021-2033)
13.2.8.5. Market Revenue and Forecast, by End User (2021-2033)
13.2.9. Rest of Europe
13.2.9.1. Market Revenue and Forecast, by Product (2021-2033)
13.2.9.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.2.9.3. Market Revenue and Forecast, by Application (2021-2033)
13.2.9.4. Market Revenue and Forecast, by Technology (2021-2033)
13.2.9.5. Market Revenue and Forecast, by End User (2021-2033)
13.3. APAC
13.3.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.3.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.4. Market Revenue and Forecast, by Technology (2021-2033)
13.3.5. Market Revenue and Forecast, by End User (2021-2033)
13.3.6. India
13.3.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.3.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.6.4. Market Revenue and Forecast, by Technology (2021-2033)
13.3.6.5. Market Revenue and Forecast, by End User (2021-2033)
13.3.7. China
13.3.7.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.3.7.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.7.4. Market Revenue and Forecast, by Technology (2021-2033)
13.3.7.5. Market Revenue and Forecast, by End User (2021-2033)
13.3.8. Japan
13.3.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.8.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.3.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.8.4. Market Revenue and Forecast, by Technology (2021-2033)
13.3.8.5. Market Revenue and Forecast, by End User (2021-2033)
13.3.9. Rest of APAC
13.3.9.1. Market Revenue and Forecast, by Product (2021-2033)
13.3.9.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.3.9.3. Market Revenue and Forecast, by Application (2021-2033)
13.3.9.4. Market Revenue and Forecast, by Technology (2021-2033)
13.3.9.5. Market Revenue and Forecast, by End User (2021-2033)
13.4. MEA
13.4.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.4.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.4. Market Revenue and Forecast, by Technology (2021-2033)
13.4.5. Market Revenue and Forecast, by End User (2021-2033)
13.4.6. GCC
13.4.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.4.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.6.4. Market Revenue and Forecast, by Technology (2021-2033)
13.4.6.5. Market Revenue and Forecast, by End User (2021-2033)
13.4.7. North Africa
13.4.7.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.4.7.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.7.4. Market Revenue and Forecast, by Technology (2021-2033)
13.4.7.5. Market Revenue and Forecast, by End User (2021-2033)
13.4.8. South Africa
13.4.8.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.8.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.4.8.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.8.4. Market Revenue and Forecast, by Technology (2021-2033)
13.4.8.5. Market Revenue and Forecast, by End User (2021-2033)
13.4.9. Rest of MEA
13.4.9.1. Market Revenue and Forecast, by Product (2021-2033)
13.4.9.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.4.9.3. Market Revenue and Forecast, by Application (2021-2033)
13.4.9.4. Market Revenue and Forecast, by Technology (2021-2033)
13.4.9.5. Market Revenue and Forecast, by End User (2021-2033)
13.5. Latin America
13.5.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.5.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.4. Market Revenue and Forecast, by Technology (2021-2033)
13.5.5. Market Revenue and Forecast, by End User (2021-2033)
13.5.6. Brazil
13.5.6.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.6.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.5.6.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.6.4. Market Revenue and Forecast, by Technology (2021-2033)
13.5.6.5. Market Revenue and Forecast, by End User (2021-2033)
13.5.7. Rest of LATAM
13.5.7.1. Market Revenue and Forecast, by Product (2021-2033)
13.5.7.2. Market Revenue and Forecast, by Therapy Type (2021-2033)
13.5.7.3. Market Revenue and Forecast, by Application (2021-2033)
13.5.7.4. Market Revenue and Forecast, by Technology (2021-2033)
13.5.7.5. Market Revenue and Forecast, by End User (2021-2033)
Chapter 14. Company Profiles
14.1. Caladrius
14.1.1. Company Overview
14.1.2. Product Offerings
14.1.3. Financial Performance
14.1.4. Recent Initiatives
14.2. CELGENE CORPORATION
14.2.1. Company Overview
14.2.2. Product Offerings
14.2.3. Financial Performance
14.2.4. Recent Initiatives
14.3. ReNeuron Group plc
14.3.1. Company Overview
14.3.2. Product Offerings
14.3.3. Financial Performance
14.3.4. Recent Initiatives
14.4. Virgin Health Bank
14.4.1. Company Overview
14.4.2. Product Offerings
14.4.3. Financial Performance
14.4.4. Recent Initiatives
14.5. Opexa Therapeutics, Inc
14.5.1. Company Overview
14.5.2. Product Offerings
14.5.3. Financial Performance
14.5.4. Recent Initiatives
14.6. Pluristem Therapeutics Inc
14.6.1. Company Overview
14.6.2. Product Offerings
14.6.3. Financial Performance
14.6.4. Recent Initiatives
14.7. STEMCELL Technologies Inc.
14.7.1. Company Overview
14.7.2. Product Offerings
14.7.3. Financial Performance
14.7.4. Recent Initiatives
14.8. Biovault family
14.8.1. Company Overview
14.8.2. Product Offerings
14.8.3. Financial Performance
14.8.4. Recent Initiatives
14.9. Precious Cells International Ltd
14.9.1. Company Overview
14.9.2. Product Offerings
14.9.3. Financial Performance
14.9.4. Recent Initiatives
14.10. Mesoblast Ltd
14.10.1. Company Overview
14.10.2. Product Offerings
14.10.3. Financial Performance
14.10.4. Recent Initiatives
Chapter 15. Research Methodology
15.1. Primary Research
15.2. Secondary Research
15.3. Assumptions
Chapter 16. Appendix
16.1. About Us
16.2. Glossary of Terms